Moderna stock surges 17% on coronavirus vaccine trial news

Moderna stock surges 17% on coronavirus vaccine trial news

14 Jul    Finance News

Moderna Inc. stock skyrocketed in the extended session Tuesday after the biotech company said its experimental coronavirus vaccine produced a “robust” immune-system response in a larger group of people and the study will move to a larger clinical trial in July.

Results published in The New England Journal of Medicine showed that a two-dose vaccination schedule induced the desired immune response in all 45 people evaluated, a larger group than in the preliminary data Moderna MRNA, +4.54% released in May, and was generally safe and well-tolerated.

Shares of Moderna ended the regular trading day up 4.5%.

See also  A mink may have infected a second Dutch worker with coronavirus, agriculture minister says

Leave a Reply

Your email address will not be published. Required fields are marked *